BC Innovations | Aug 29, 2019
Distillery Therapeutics

MLANA-loaded nanoparticle vaccine plus mAbs against PD-1 and OX40 to sensitize melanoma to Imbruvica

DISEASE CATEGORY: Cancer INDICATION: Melanoma Immunization with an MLANA-loaded nanoparticle vaccine in combination with mAbs against PD-1 and OX40 could sensitize melanomas to Imbruvica ibrutinib. The vaccine consists of polylactic-co-glycolic acid polymer nanoparticles loaded with...
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BC Innovations | May 23, 2018
Distillery Therapeutics


INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
BC Innovations | Feb 28, 2018
Distillery Techniques


TECHNOLOGY: Plasma markers Detection of a panel of circulating tumor cell (CTC)-derived RNA transcripts in blood could help predict survival and disease progression in metastatic melanoma patients receiving immune checkpoint inhibitors. The method scores blood...
BC Innovations | Oct 12, 2017
Translation in Brief

Opening doors for I-O

A Science Translational Medicine study has flipped the script for tumor lymphangiogenesis by turning VEGF-C , a hallmark of poor prognosis, into a biomarker and a target for successful responses to immunotherapies. Tumors that are surrounded...
BC Innovations | Oct 3, 2017
Distillery Techniques


TECHNOLOGY: Plasma markers Serum levels of VEGF-C could help predict responses to immunotherapies in patients with solid tumors. In sera from 20 metastatic melanoma patients vaccinated with melan-A ( MLANA ; MART1) peptide and the toll-like...
BC Innovations | Jun 7, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Other An S. typhimurium -based DNA vaccine vector expressing tumor antigens and Bacterial AIDA-I autotransporter (AIDA-I) could be used to deliver cancer vaccines. The vaccine vector consisted of an attenuated S. typhimurium strain engineered...
BC Innovations | Apr 30, 2015
Distillery Techniques

Techniques: Deoxycytidine kinase (DCK)-based in vivo PET imaging of T cell immunotherapies

Imaging TECHNOLOGY: PET T cells engineered to express a PET imaging reporter could help monitor tumor infiltration of chimeric antigen receptor (CAR) and other T cell immunotherapies. Cells expressing a triple mutant of human DCK...
BC Innovations | Jan 8, 2015
Distillery Techniques

Techniques: Evolved T-cell receptor (TCR) variants

Drug platforms TECHNOLOGY: Antibody scaffolds Directed evolution of single TCRs could be used to generate variants with novel binding specificities without the need to isolate T cell clones. In vitro, genetically modified variants of a...
BC Innovations | Feb 7, 2013
Tools & Techniques

Rejuvenating T cells

Two Japanese teams have used induced pluripotent stem cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. 1,2 Megakaryon Corp. is developing and commercializing the technology of one group to...
Items per page:
1 - 10 of 34